BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15379547)

  • 1. The drug-binding pocket of the human multidrug resistance P-glycoprotein is accessible to the aqueous medium.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2004 Sep; 43(38):12081-9. PubMed ID: 15379547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket.
    Loo TW; Bartlett MC; Clarke DM
    Biochem J; 2006 Oct; 399(2):351-9. PubMed ID: 16813563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2007 Aug; 46(32):9328-36. PubMed ID: 17636884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATP hydrolysis promotes interactions between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2005 Aug; 44(30):10250-8. PubMed ID: 16042402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket.
    Loo TW; Bartlett MC; Clarke DM
    Biochem J; 2006 Jun; 396(3):537-45. PubMed ID: 16492138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human P-glycoprotein is active when the two halves are clamped together in the closed conformation.
    Loo TW; Bartlett MC; Clarke DM
    Biochem Biophys Res Commun; 2010 May; 395(3):436-40. PubMed ID: 20394729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Permanent activation of the human P-glycoprotein by covalent modification of a residue in the drug-binding site.
    Loo TW; Bartlett MC; Clarke DM
    J Biol Chem; 2003 Jun; 278(23):20449-52. PubMed ID: 12711602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains.
    Liu R; Sharom FJ
    Biochemistry; 1996 Sep; 35(36):11865-73. PubMed ID: 8794769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cysteine-scanning mutagenesis and thiol modification of the Rickettsia prowazekii ATP/ADP translocase: evidence that TM VIII faces an aqueous channel.
    Winkler HH; Daugherty RM; Audia JP
    Biochemistry; 2003 Nov; 42(43):12562-9. PubMed ID: 14580202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
    Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
    Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?
    Loo TW; Clarke DM
    Biochem Biophys Res Commun; 2005 Apr; 329(2):419-22. PubMed ID: 15737603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane.
    Loo TW; Bartlett MC; Clarke DM
    J Biol Chem; 2004 Feb; 279(9):7692-7. PubMed ID: 14670948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of cysteines involved in the effects of methanethiosulfonate reagents on human equilibrative nucleoside transporter 1.
    Park JS; Hughes SJ; Cunningham FK; Hammond JR
    Mol Pharmacol; 2011 Oct; 80(4):735-46. PubMed ID: 21791574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleotide binding to the multidrug resistance P-glycoprotein as studied by ESR spectroscopy.
    Delannoy S; Urbatsch IL; Tombline G; Senior AE; Vogel PD
    Biochemistry; 2005 Oct; 44(42):14010-9. PubMed ID: 16229490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methanethiosulfonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites.
    Loo TW; Bartlett MC; Clarke DM
    J Biol Chem; 2003 Dec; 278(50):50136-41. PubMed ID: 14522974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug binding and nucleotide hydrolyzability are essential requirements in the vanadate-induced inhibition of the human P-glycoprotein ATPase.
    Rao US
    Biochemistry; 1998 Oct; 37(42):14981-8. PubMed ID: 9778376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vanadate trapping of nucleotide at the ATP-binding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding site.
    Loo TW; Clarke DM
    Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3511-6. PubMed ID: 11891276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
    Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
    Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cysteine-scanning mutagenesis and thiol modification of the Rickettsia prowazekii ATP/ADP translocase: characterization of TMs IV-VII and IX-XII and their accessibility to the aqueous translocation pathway.
    Audia JP; Roberts RA; Winkler HH
    Biochemistry; 2006 Feb; 45(8):2648-56. PubMed ID: 16489758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane.
    Loo TW; Clarke DM
    J Biol Chem; 2000 Dec; 275(50):39272-8. PubMed ID: 11013259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.